Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 2:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–19 of 19 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Completed Phase 2Phase 3 Interventional Results available

Benralizumab for Eosinophilic Gastritis (BEGS)

NCT03473977
Conditions
Eosinophilic Gastritis or Gastroenteritis
Interventions
Benralizumab, Placebo
Biological
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
12 Years to 60 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Solid Tumor, Solid Carcinoma, Solid Tumor, Adult, Hematologic Malignancy
Interventions
Benralizumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 85 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 2 more
Conditions
ABPA, Severe Asthma, Allergic Bronchopulmonary Aspergillosis
Interventions
Fasenra, 30 Mg/mL Subcutaneous Solution
Drug
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Active, not recruiting Phase 3 Interventional Results available

Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab.

NCT04157348
Conditions
Eosinophilic Granulomatous Vasculitis
Interventions
Benralizumab, Mepolizumab, Placebo to Mepolizumab, Placebo to Benralizumab
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
9
States / cities
Denver, Colorado • Ann Arbor, Michigan • Rochester, Minnesota + 6 more
Conditions
Asthma
Interventions
Benralizumab
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
12
States / cities
Fountain Valley, California • Walnut Creek, California • Celebration, Florida + 9 more
Conditions
Asthma
Interventions
Benralizumab, Placebo
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 75 Years
Enrollment
2,508 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
81
States / cities
Andalusia, Alabama • Birmingham, Alabama • Flagstaff, Arizona + 78 more
Conditions
Nasal Polyposis
Interventions
Benralizumab 30 mg SC + Mometasone Furoate, Matching placebo SC + Mometasone Furoate
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
48
States / cities
Birmingham, Alabama • Fresno, California • Huntington Beach, California + 37 more
Conditions
Asthma
Interventions
Benralizumab, Placebo
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 75 Years
Enrollment
2,681 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
110
States / cities
Foley, Alabama • Huntsville, Alabama • Mobile, Alabama + 107 more
Conditions
Asthma
Interventions
Benralizumab
Drug
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years to 100 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Denver, Colorado
Conditions
Moderate to Severe Asthma
Interventions
Dupilumab, Benralizumab
Biological
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
3
States / cities
Scottsdale, Arizona • La Jolla, California • New Haven, Connecticut
Conditions
Asthma
Interventions
Benralizumab, Placebo
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
21
States / cities
Birmingham, Alabama • Glendale, Arizona • San Jose, California + 18 more
Conditions
Asthma
Interventions
Placebo, Benralizumab
Other · Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
9
States / cities
Tampa, Florida • Springfield, Massachusetts • Detroit, Michigan + 6 more
Conditions
Asthma
Interventions
Benralizumab (Medi-563), Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
100
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 87 more
Conditions
Asthma
Interventions
Benralizumab
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
598 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
23
States / cities
Flagstaff, Arizona • Los Angeles, California • Aurora, Colorado + 20 more
Conditions
Eosinophilic Asthma
Interventions
ICS-LABA, benralizumab, Placebo for Benralizumab
Combination Product
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 75 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
34
States / cities
Chandler, Arizona • Sun City, Arizona • Tucson, Arizona + 28 more
Conditions
Asthma
Interventions
Benralizumab, Placebo
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
19
States / cities
Birmingham, Alabama • Los Angeles, California • Jacksonville, Florida + 16 more
Conditions
Nasal Polyposis, Eosinophilic Chronic Rhinosinusitis
Interventions
Benralizumab 30 mg, Matched placebo
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
15
States / cities
Huntington Beach, California • Grand Junction, Colorado • Gainesville, Florida + 12 more
Conditions
Asthma
Interventions
Benralizumab
Combination Product
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
10
States / cities
Walnut Creek, California • Loxahatchee Groves, Florida • Plantation, Florida + 7 more
Conditions
Asthma
Interventions
GSK3511294 (Depemokimab), Mepolizumab, Benralizumab, Placebo, Standard of care (SoC), Pre-filled Syringes (PFS)
Biological · Drug · Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
1,717 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
119
States / cities
Birmingham, Alabama • Scottsboro, Alabama • Litchfield Park, Arizona + 94 more